CBHD.XETRA Coloplast A/S
- Market cap
- EUR 15.1B
- P/E
- 36.6x
- P/B
- 8.18x
- ROE
- 21.5%
- Dividend yield
- 4.44%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2026.
Is CBHD.XETRA undervalued?
Graham numberThe Graham number of Coloplast A/S cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Coloplast A/S fundamental analysis
No fundamental analysis for Coloplast A/S yet.
Coloplast A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of osto…
Full company profileColoplast A/S financial statements
Coloplast A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 15.5B | 16.4B | 17.9B | 18.5B | 19.4B | 22.6B | 24.5B | 27.0B | 27.8B | 28.9B |
| Gross Profit | 10.6B | 11.1B | 12.2B | 12.6B | 13.3B | 15.5B | 16.3B | 18.3B | 18.1B | 19.2B |
| Operating Income | 5.02B | 5.09B | 5.16B | 5.85B | 6.36B | 6.44B | 6.77B | 7.32B | 7.56B | 7.34B |
| EBITDA | 5.57B | 5.65B | 5.69B | 6.35B | 7.05B | 7.23B | 7.73B | 8.48B | 8.32B | 11.8B |
| Net Income | 3.80B | 3.85B | 3.87B | 4.20B | 4.83B | 4.71B | 4.78B | 5.05B | 3.63B | 3.07B |
| EPS | 18 | 18 | 18 | 20 | 23 | 22 | 22 | 22 | 16 | 14 |
| Balance Sheet | ||||||||||
| Total Assets | 12.1B | 11.8B | 12.7B | 13.5B | 15.8B | 35.0B | 48.2B | 48.1B | 48.2B | 46.2B |
| Total Liabilities | 6.10B | 5.35B | 5.82B | 6.09B | 7.67B | 26.7B | 30.9B | 30.1B | 32.2B | 31.9B |
| Shareholders' Equity | 5.95B | 6.42B | 6.91B | 7.41B | 8.17B | 8.29B | 17.3B | 17.9B | 16.1B | 14.3B |
| Cash & Short-term Investments | 629M | 607M | 669M | 585M | 674M | 633M | 911M | 788M | 945M | 510M |
| Total Debt | 1.46B | 1.36B | 1.21B | 1.75B | 2.79B | 18.7B | 19.6B | 22.6B | 22.6B | 21.5B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.25B | 4.36B | 4.36B | 4.76B | 5.29B | 5.10B | 4.23B | 2.77B | 6.63B | 7.98B |
| Capital Expenditure | 685M | 669M | 636M | 931M | 1.97B | 1.14B | 1.24B | 1.35B | 1.30B | 1.38B |
| Free Cash Flow | 2.57B | 3.69B | 3.72B | 3.83B | 3.32B | 3.96B | 2.99B | 1.42B | 5.33B | 6.60B |
| Ratios | ||||||||||
| ROE | 63.8% | 59.9% | 56.0% | 56.7% | 59.1% | 56.8% | 27.6% | 28.2% | 22.6% | 21.5% |
| ROA | 31.5% | 32.7% | 30.4% | 31.1% | 30.5% | 13.5% | 9.9% | 10.5% | 7.5% | 6.6% |
| Net Profit Margin | 24.5% | 23.4% | 21.6% | 22.6% | 24.8% | 20.8% | 19.5% | 18.7% | 13.0% | 10.6% |
| Debt to Equity | 0.24x | 0.21x | 0.17x | 0.24x | 0.34x | 2.26x | 1.13x | 1.26x | 1.40x | 1.51x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Coloplast A/S dividends
- Dividend yield
- 4.44%
- Forward dividend
- 3.08 EUR
- Payout ratio
- 168.6%
- Ex-dividend date
- May 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | DKK 5.17B | 23 | 168.6% |
| 2025 | DKK 4.95B | 22 | 136.4% |
| 2024 | DKK 4.72B | 21 | 93.4% |
| 2023 | DKK 4.25B | 20 | 88.8% |
| 2022 | DKK 4.04B | 19 | 85.9% |
| 2021 | DKK 3.83B | 18 | 79.4% |
| 2020 | DKK 3.61B | 17 | 86.1% |
| 2019 | DKK 3.40B | 16 | 87.7% |
| 2018 | DKK 3.29B | 15 | 85.5% |
| 2017 | DKK 2.86B | 13 | 75.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Dec 19, 2012.
Who owns Coloplast A/S
- Insiders 29.80%
- Institutions 29.55%
- Public & others 40.65%
- Shares outstanding 207M
- Free float 145M
Coloplast A/S company profile
- Company name
- Coloplast A/S
- Ticker
- CBHD.XETRA
- ISIN
- DK0060448595
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 17,522
- Fiscal year end
- September
- Address
- Holtedam 1-3, Humlebæk, Denmark, 3050
- Phone
- 45 49 11 11 11
- Website
- coloplast.com
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Coloplast A/S management
2- Mr. Alain MorvanSenior Vice President of Sales Europe
- Ms. Caroline Vagner RosenstandExecutive Vice President of Chronic Care Commercial · born 1979